WeTrials
Recruiting

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

What is this study?

This study is testing if adding a chemotherapy medicine called docetaxel to standard hormone treatments can better slow down the growth of prostate cancer. Researchers want to see if this combined approach works better than the usual treatments alone for patients who still have elevated PSA levels.

Who can participate?

You might be able to join if you have prostate cancer that has spread to other parts of the body and your PSA levels remain at 2.0 or higher after starting hormone therapy. Participants must not have prior treatment with certain types of chemotherapy or moderate to severe nerve damage in their hands and feet.

What will happen?

Participants will receive either the standard hormone therapy alone or hormone therapy combined with the chemotherapy drug docetaxel. Your health and cancer response will be closely monitored by the study doctors throughout the process.

Where and when?

This study is currently recruiting patients and takes place in locations including Anchorage, Alaska in the United States.

Key Points
  • 1Testing if adding chemotherapy to hormone therapy improves prostate cancer treatment
  • 2Open to patients whose cancer has spread and who have a suboptimal PSA response
  • 3Currently recruiting participants at select locations

Related videos

2

P2PMD: study chair Michael Ong explains the TRIPLE-SWITCH (PR.26) design at ASCO 2025 (June 2025)

Urology Times: co-chair Alexandra Sokolova on why the TRIPLE-SWITCH trial is needed (December 2025)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Prostate Cancer (Adenocarcinoma)

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.